Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Sanofi

Status and phase

Completed

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: insulin glulisine

Study type

Interventional

Funder types

Industry

Identifiers

EFC6168

Details and patient eligibility

About

To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy.
To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy.
To evaluate the safety of HMR1964.

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men or women with type 2 diabetes mellitus diagnosed at least one year prior to the study with a BMI < 30 kg/m2 , a HbA1C of > 8.0 - < 11.0% at screening
Fasting serum C-peptide at screening > 0.7 ng/mL
Subjects who have been on a stable regimen and at the following doses of SU for at least 8 weeks prior to signing informed consent
Glibenclamide > 5 mg/day
Glimepiride > 3 mg/day
Gliclazide > 80 mg/day In addition to receiving the above mentioned SU agents, subjects may have been treated with a biguanide at a stable dose for at least 8 weeks prior to signing informed consent.
Subjects willing to administer three HMR1964 injections per day immediately prior to meals for a 16 week

Exclusion criteria

Subjects unwilling or incapable of receiving a starting dose of ≥ 0.2 IU/kg/day of HMR1964
Subjects with the likelihood of requiring concomitant treatment during the study period with the following classes of drugs: additional OHA (including thiazolidinediones, α-glucosidase inhibitors, D-phenylalanine derivative) other than those specified in the study protocol, insulin preparations other than HMR1964, systemic corticosteroids, other investigational products
Subjects with clinically relevant cardiovascular, hepatic, neurologic, endocrine diseases; and active cancer; or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
Subjects who are pregnant, breast feeding or wish to become pregnant during the study period
Subjects with diabetic retinopathy who received surgical treatments (laser photocoagulation or vitrectomy) within 12 weeks prior to informed consent, who are expected to have these surgical treatments during the study period, or who were diagnosed newly proliferative diabetic retinopathy within 12 weeks prior to informed consent